That is soon in the FDA clinical trial world. All you dopes talking about many years are completely wrong
I agree. Even though the SEC filing states the J&J deal does not prevent an acquisition offer from another company it is highly unlikely since Geron has transferred all Imetelstat development to J&J and Geron no longer has R&D
If you plan on holding Geron until Imetelstat makes it to market (2+ years) it doesn't really matter whether the PPS is $4 or $6 right now. Geron has plenty of cash and doesn't need to pump the PPS to float a secondary.
Wall Street will value this company based on potential future revenue as the path to approval becomes more certain and the size of the market is more predictable.
oops typo ... meant "Chip and Huh interested in the long term value ....."
Chip and Huh the long term value of the company as IMET comes to market. They are not likely interested in appeasing a bunch of message board loons freaking out with every PPS gyration.
There's no stock market conspiracy going on here. As the probability of Imetelstat approval increases so will the stock. 600 mil market cap is about right for a promising phase 2 company. I believe approval of Imetelstat is certain but until the market believes that there is opportunity to acquire mire shares
I don't think it is appropriate to solicit dates on this message board. Craig's list might be more appropriate.
"Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor" (Title of the study)
I would assume "previously" means not currently receiving JAK inhibitor. Seems clear to me
Don't understand what you are trying to say. I'm talking about clinical research ... so what if he harmed a few rats along the way.
He follows the science and doesn't let the standard norms get in the way. That is why he has the most promising Stem cell IP while others allow the direction of their research to be influenced by politics and religion.
For sure not too exciting. NVIV's trial where patients are recovering motor movement and bladder and bowel function is where the action is right now.
I have read a lot of the Longecity messages also. It looks very positive. I was surprised how easy it is to get a lab to make it for you.
Interesting discussion. Im preclinical research throughout universities and elsewhere in many studies it has been shown to shorten telomeres. However, Geron (Chip in particular) has never stated that that is the case in clinical trials. From Chip's standpoint as a CEO who has a history of selling off companies it really doesn't matter. What matters is whether Imetelstat is a drug that can be proven to work and ultimately get approval from the FDA.
Companies don't issue multiple PRs about single patients. At least not legit companies. They need approval from the FDA not social media and company PRs. The FDA frowns on over pumping preliminary results. I agree that 2 out of 2 with impressive results makes this an obvious investment choice and I have bought more. Given that 1 in 10 normally have these results it is a 1 in 100 (10x10) chance that it is by chance and a 99% chance it is the scaffold. Just take advantage of your knowledge and buy more if you can.
Those share were distributed to Geron holders. Relying on Yahoo for financial data on companies is silly.